Search
Influenza A virus A/Uruguay/716/2007(H3N2) hemagglutinin antigen (UV,formaldehyde inactivated)
go.drugbank.com/drugs/DB14699ApprovedWithdrawnIn contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Indiana/08/2018 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB15506ApprovedWithdrawnIn contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Kansas/14/2017 (H3N2) live (attenuated) antigen
go.drugbank.com/drugs/DB15514ApprovedWithdrawnIn contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Brisbane/02/2018 (H1N1) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB15517ApprovedWithdrawnIn contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Kansas/14/2017 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB15518ApprovedWithdrawnIn contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/North carolina/04/2016 (H3N2) hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB15562ApprovedIn contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Washington/02/2019 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15620ApprovedInvestigationalIn contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/South Australia/34/2019 IVR-197 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15621ApprovedWithdrawnIn contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Hawaii/70/2019 (H1N1) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB15700ApprovedWithdrawnIn contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Hong Kong/2671/2019 IVR-208 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15704ApprovedInvestigationalIn contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.